Momenta Pharmaceuticals, Inc. (MNTA): Price and Financial Metrics

Momenta Pharmaceuticals, Inc. (MNTA): $52.48

0.01 (-0.02%)

POWR Rating

Component Grades








Add MNTA to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

MNTA Price/Volume Stats

Current price $52.48 52-week high $52.53
Prev. close $52.49 52-week low $12.21
Day low $52.46 Volume 8,010,600
Day high $52.53 Avg. volume 1,939,894
50-day MA $43.52 Dividend yield N/A
200-day MA $32.97 Market Cap 6.25B

MNTA Stock Price Chart Interactive Chart >

Momenta Pharmaceuticals, Inc. (MNTA) Company Bio

Momenta Pharmaceuticals is specializing in the detailed structural analysis of complex drugs and applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. The company was founded in 2001 and is based in Cambridge, Massachusetts.

MNTA Latest News Stream

Event/Time News Detail
Loading, please wait...

MNTA Latest Social Stream

Loading social stream, please wait...

View Full MNTA Social Stream

Latest MNTA News From Around the Web

Below are the latest news stories about Momenta Pharmaceuticals Inc that investors may wish to consider to help them evaluate MNTA as an investment opportunity.

Johnson & Johnson to Buy Drug Maker Momenta Pharmaceuticals for $6.5 Billion

It will reportedly be the largest pharma deal to date in 2020, topping Gilead’s $4.9 billion buy of Forty Seven.

Thomasnet | August 25, 2020

Momenta Pharmaceuticals leads healthcare gainers; Eyenovia and Galapagos among losers

Gainers: Momenta Pharmaceuticals (MNTA) +69%. iRhythm Technologies (IRTC) +18%. DarioHealth (DRIO) +16%. Verrica Pharmaceuticals (VRCA) +16%. Avalon GloboCare (AVCO) +15%.Losers: BioMarin Pharmaceutical (BMRN) -33%. Galapagos (GLPG) -23%. Eyenovia (EYEN) -19%. Timber Pharmaceuticals (TMBR) -11%. Scworx (WORX) -10%....

Seeking Alpha | August 19, 2020

J&J buying Momenta in a $6.5B all-cash deal

Johnson & Johnson is buying Momenta Pharmaceuticals in a major all-cash deal. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani discuss.

Yahoo Finance | August 19, 2020

Johnson & Johnson to buy Momenta for about US$6.5 billion

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about US$6.5 billion in cash to expand into the area of autoimmune disease treatments.

Channel NewsAsia | August 19, 2020

Momenta Pharmaceuticals' stock rockets after $6.5 billion buyout deal with Johnson & Johnson

Shares of Momenta Pharmaceuticals Inc. undefined rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced…

MarketWatch | August 19, 2020

Read More 'MNTA' Stories Here

MNTA Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year 351.25%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 78.71%

Continue Researching MNTA

Want to see what other sources are saying about Momenta Pharmaceuticals Inc's financials and stock price? Try the links below:

Momenta Pharmaceuticals Inc (MNTA) Stock Price | Nasdaq
Momenta Pharmaceuticals Inc (MNTA) Stock Quote, History and News - Yahoo Finance
Momenta Pharmaceuticals Inc (MNTA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!